KEY TAKEAWAYS
- The study aimed to assess if postoperative ACT lowers recurrence in Stage I lung adeno with MIP, improving OS and DFS.
- Patients with stage I lung adeno and MIP components derive notable benefits from ACT, particularly when MIP presence was ≥1%.
The efficacy of postoperative adjuvant chemotherapy (ACT) in lung cancer patients (stage I adenocarcinoma) (adeno) containing micropapillary (MIP) components remains uncertain.
Ying Li and the team aimed to assess if postoperative ACT could decrease recurrence in stage I lung adeno with MIP, thus enhancing overall survival (OS) and disease-free survival(DFS).
The study retrospectively analyzed data from January 2012 to December 2018 for patients diagnosed with stage I lung adeno with MIP components. They examined OS and DFS in various groups and subgroups.
About 259 patients were included. Patients who underwent ACT in stage IA demonstrated significantly improved survival compared to those with no (N) ACT: (5-year OS 89.4% vs. 73.6%, P< 0.001; 5-year DFS 87.2% vs. 66.0%, P= 0.008). Similar differences were noted in stage IB patients: (5-year OS 82.0% vs. 51.8%, P= 0.001; 5-year DFS 76.0% vs. 41.11%, P = 0.004).
The subgroup analysis based on the proportion of MIP components revealed that patients with 1%-5% MIP had significantly improved outcomes in the ACT group compared to the NACT group: (5-year OS 82.4% vs. 66.0%, P = 0.005; 5-year DFS 76.5% vs. 49.1%, P = 0.032). Similarly, patients with MIP ≥5% also showed better outcomes with ACT: (5-year OS 80.7% vs. 47.8%, P= 0.009; 5-year DFS 73.11% vs. 43.5%, P = 0.007).
The study concluded that patients diagnosed with stage I lung adeno featuring MIP components experienced notable survival advantages with ACT compared to those without ACT. Furthermore, patients with lung adeno and MIP components could benefit from ACT, particularly when MIP presence was ≥1%.
Research received support from the National Natural Science Foundation of China and the Natural Science Foundation of Shandong Province.
Source: https://pubmed.ncbi.nlm.nih.gov/38400663/
Li Y, Zhao J, Zhao Y, et al. (2024) ‘’Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.’’ Cancer Med. 2024 Feb;13(3):e7030. doi: 10.1002/cam4.7030.
